News

reMYND launches a project aimed at improving the predictability of preclinical Alzheimer models as part of the prestigious Marie-Curie International Training Network NPlast

06-09-2012
Press release | reMYND NV announced today its project in NPlast, a prestigious International Training Network funded by the European Commission that is to be launched April 27-28th 2012 at the Leibniz-Institut für Neurobiologie in Magdeburg, Germany.

Ajit Shetty strengthens reMYND’s Board of Directors

21-08-2012
Press release | reMYND NV today announced that its shareholders have elected Ajit Shetty to join the company’s 4-person Board as an Independent Director.

reMYND receives a positive tax ruling on the income from its Roche collaboration

31-01-2012
In the press | reMYND NV has received a positive ruling from the Belgian Tax Authorities. The ruling stipulates that the upfront license fee, all milestone payments and royalties linked to Roche Basel will qualify for the patent income deduction under Articles 205 WIB 92.

The strategic alliance between Roche and reMYND is nominated for a Scrip Award

29-09-2011
In the press | The strategic Alliance between Roche and reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients is nominated for the Scrip Award “Best Partnership Alliance”. The winners will be announced in London on November 3rd, 2011.

reMYND’s grant from the Michael J Fox Foundation in SciBX

17-08-2011
In the press | The Science-Business eXchange (SciBX, a publication by the makers of BioCentury and Nature) devoted in its recent publication an article to the role the Michael J Fox Foundation for Parkinson’s Research has been playing in the development of PD therapeutics.

Pages